Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
4.500
-0.250 (-5.26%)
At close: Oct 17, 2025, 4:00 PM EDT
4.510
+0.010 (0.22%)
After-hours: Oct 17, 2025, 6:17 PM EDT
Cellectar Biosciences Market Cap
Cellectar Biosciences has a market cap or net worth of $14.36 million as of October 17, 2025. Its market cap has decreased by -80.75% in one year.
Market Cap
14.36M
Enterprise Value
3.87M
1-Year Change
-80.75%
Ranking
Category
Stock Price
$4.50
Market Cap Chart
Since November 10, 2005, Cellectar Biosciences's market cap has increased from $7.50M to $14.36M, an increase of 91.52%. That is a compound annual growth rate of 3.31%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 16, 2025 | 15.20M | 23.58% |
| Dec 31, 2024 | 12.30M | -63.82% |
| Dec 29, 2023 | 34.00M | 112.50% |
| Dec 30, 2022 | 16.00M | -60.59% |
| Dec 31, 2021 | 40.60M | -27.24% |
| Dec 31, 2020 | 55.80M | 164.45% |
| Dec 31, 2019 | 21.10M | 185.14% |
| Dec 31, 2018 | 7.40M | -65.90% |
| Dec 29, 2017 | 21.70M | 233.85% |
| Dec 30, 2016 | 6.50M | 3.17% |
| Dec 31, 2015 | 6.30M | -73.08% |
| Dec 31, 2014 | 23.40M | 9.86% |
| Dec 31, 2013 | 21.30M | -37.72% |
| Dec 31, 2012 | 34.20M | 187.39% |
| Dec 30, 2011 | 11.90M | 325.00% |
| Dec 31, 2010 | 2.80M | -98.80% |
| Dec 31, 2009 | 233.20M | 2,164.08% |
| Dec 31, 2008 | 10.30M | -56.90% |
| Dec 31, 2007 | 23.90M | -22.90% |
| Dec 29, 2006 | 31.00M | -30.49% |
| Dec 30, 2005 | 44.60M | 494.67% |
| Nov 10, 2005 | 7.50M | - |
View and export this data all the way back to 2005. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 735.59B |
| Johnson & Johnson | 462.69B |
| AbbVie | 400.78B |
| UnitedHealth Group | 323.03B |
| AstraZeneca | 261.44B |
| Novo Nordisk | 254.14B |
| Novartis AG | 253.93B |
| Abbott Laboratories | 222.13B |